Mefenamic acid, a BCS Class II drug, continues to face the longstanding challenges related to its suboptimal solubility and variable absorption, which necessitates frequent dosing of the drug resulting in ulcerogenicity. Guided by its polymorphic forms, the co... ...

请注册登录后继续浏览